Company profile
Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology: Pharmaceutical Preparations
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05226507 | phase1 | terminated | 2021-12-31 | 2025-01-01 | Nuvectis Pharma, Inc. | A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer |
| NCT05873686 | phase1 | recruiting | 2023-10-26 | 2027-03-01 | Nuvectis Pharma, Inc. | A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers |
| NCT07784959 | phase1 | recruiting | 2026-08-17 | 2027-08-01 | Nuvectis Pharma, Inc. | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer |
| NCT07315113 | phase1 | recruiting | 2025-12-18 | 2026-12-01 | Nuvectis Pharma, Inc. | Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer |
FDA applications (0)
No records yet.